While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Importantly, the combination of giredestrant and everolimus was well tolerated
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Subscribe To Our Newsletter & Stay Updated
